Charles Schwab’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-210,259
| Closed | -$20.4M | – | 3192 |
|
|
2019
Q3 | $20.4M | Buy |
210,259
+15,755
| +8% | +$1.58M | 0.01% | 1135 |
|
|
2019
Q2 | $19.9M | Buy |
194,504
+8,709
| +5% | +$940K | 0.01% | 1143 |
|
|
2019
Q1 | $21.2M | Buy |
185,795
+11,495
| +7% | +$845K | 0.01% | 1065 |
|
|
2018
Q4 | $6.82M | Sell |
174,300
-1,101
| -0.6% | -$47.8K | 0.01% | 1713 |
|
|
2018
Q3 | $9.57M | Buy |
175,401
+10,137
| +6% | +$693K | 0.01% | 1673 |
|
|
2018
Q2 | $13.7M | Buy |
165,264
+13,894
| +9% | +$1.07M | 0.01% | 1375 |
|
|
2018
Q1 | $10.1M | Buy |
151,370
+6,738
| +5% | +$389K | 0.01% | 1489 |
|
|
2017
Q4 | $7.44M | Buy |
144,632
+15,062
| +12% | +$1.08M | 0.01% | 1678 |
|
|
2017
Q3 | $11.6M | Buy |
129,570
+34,650
| +37% | +$2.63M | 0.01% | 1317 |
|
|
2017
Q2 | $5.67M | Buy |
94,920
+7,169
| +8% | +$401K | 0.01% | 1740 |
|
|
2017
Q1 | $4.68M | Buy |
87,751
+7,605
| +9% | +$452K | ﹤0.01% | 1796 |
|
|
2016
Q4 | $4M | Buy |
80,146
+4,216
| +6% | +$226K | ﹤0.01% | 1863 |
|
|
2016
Q3 | $4.56M | Buy |
75,930
+13,642
| +22% | +$786K | 0.01% | 1705 |
|
|
2016
Q2 | $3.19M | Buy |
62,288
+20,920
| +51% | +$894K | ﹤0.01% | 1836 |
|
|
2016
Q1 | $1.22M | Buy |
41,368
+6,829
| +20% | +$215K | ﹤0.01% | 2260 |
|
|
2015
Q4 | $1.56M | Buy |
34,539
+1,283
| +4% | +$67.2K | ﹤0.01% | 2196 |
|
|
2015
Q3 | $1.39M | Buy |
33,256
+13,180
| +66% | +$688K | ﹤0.01% | 2254 |
|
|
2015
Q2 | $1.21M | Buy |
20,076
+13,074
| +187% | +$864K | ﹤0.01% | 2332 |
|
|
2015
Q1 | $543K | Buy |
+7,002
| New | +$403K | ﹤0.01% | 2600 |
|
Charles Schwab's ONCE Position: Q4 2019 in Review
Charles Schwab sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 210,259 shares — an estimated $20.4M sold.
Charles Schwab first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $21.2M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Charles Schwab reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Charles Schwab sold 210,259 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $20.4M.
- Charles Schwab first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Charles Schwab's Spark Therapeutics, Inc. Common Stock position peaked at $21.2M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Charles Schwab's 13F filing for Q4 2019, filed 7 Feb 2020.